Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiotech Pharmaceuticals, Inc.
Recall of Taxus coronary stent system expanded
September 1st, 2004
Angiotech Pharmaceuticals, Inc.'s, (ANPI, ANP) corporate partner, Boston Scientific, provided an update on the Taxus Express(2TM) Paclitaxel-Eluting Coronary Stent System. On July 2 and 16, Boston Scientific announced the voluntary recall of certain Taxus and Express(2TM) coronary stent systems, due to characteristics in the delivery catheters that had the potential to impede balloon deflation during a coronary angioplasty procedure, a condition known as focal neckdown, and which could result in serious injury to patients. Boston Scientific announced that its own ongoing monitoring has revealed the need to expand the July 16th recall nationwide to...
Source: Biotech Week (2004-09-01)
|
